Picture

AstraZeneca - ADDC Collaboration

The collaboration allows for ADDC members to have direct access to the AstraZeneca's library of compounds.

This collaboration between ADDC and AstraZeneca is aimed at at facilitating efforts by researchers from academia and institutions towards the discovery of novel compounds with potential pharmaceutical application.
Click here for more information

Highlighted Partnerships

Research Collaboration and license agreement

Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, today announced a new research collaboration...

Research Collaboration and license agreement

The Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in...

Research collaboration and license agreement

The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for...

California Institute for Quantitative Biosciences (QB3)

 QB3 isa tri-campus organization at UC Berkeley, UC San Francisco, and UC Santa Cruz.

QB3 is the University of California’s hub for innovation and entrepreneurship in the life sciences. The...

Royal Society of Chemistry

RSC Chemical Biology

Led by Hiroaki Suga (University of Tokyo), RSC Chemical Biology is a gold open access journal, dedicated to publishing exceptionally significant and breakthrough findings of...

Number of Registered Partnerships

52

So Far
Therapeuitic Areas of Expertise
  • Choices
    Percentage
  • Oncology
     
    32.69%
  • Infectious Diseases
     
    15.38%
  • Neurological Disorders
     
    34.62%
  • Immunology
     
    23.08%
  • Metabolic Disorders
     
    21.15%
  • Cardiology
     
    13.46%
  • Pain
     
    7.69%
  • Other
     
    11.54%
  •  
Therapeutic Approaches
  • Choices
    Percentage
  • Small Molecules
     
    78.85%
  • Biologics
     
    38.46%
  • Biomarkers
     
    3.85%
  • Drug Delivery
     
    3.85%
  • Stem Cells
     
    3.85%
  • Vaccines
     
    1.92%
  • Antibodies
     
    9.62%
  • Other
     
    1.92%
  •